Abstract
Warfarin pharmacogenomic testing has become a prime example of the utility of personalized molecular testing in the modern clinical laboratory. Warfarin is a commonly used drug for the prevention and treatment of thromboembolic complications in a variety of clinical situations. However, a number of factors lead to a high interindividual variability in dose requirements. Among the primary factors in this variability are genetic polymorphisms in general patient populations, which can account for 35-50% of varying dose requirements among patients. In this review, we discuss the implications of polymorphisms in the cytochrome P-450 enzyme 2C9 (CYP2C9) and Vitamin K Epoxide Reductase Enzyme Complex subunit 1 (VKORC1) as they relate to therapeutic warfarin dosing. We discuss the clinical utility of pharmacogenomics testing as related to warfarin dosing, and propose a clinical model for the implementation of the pharmacogenomic test results. Finally, we provide a brief overview of the currently available commercial testing platforms with discussion of the complexities of utilizing patented methodologies in bringing genetic testing such as this to the clinical laboratory.
Keywords: Biotechnology, patents, pharmacogenomics, pharmacogenetics, warfarin.
Recent Patents on Biotechnology
Title:Warfarin Pharmacogenomics: Recommendations With Available Patented Clinical Technologies
Volume: 8 Issue: 2
Author(s): Andrew A. Borkowski, Avni Kardani, Stephen M. Mastorides and L. Brannon Thomas
Affiliation:
Keywords: Biotechnology, patents, pharmacogenomics, pharmacogenetics, warfarin.
Abstract: Warfarin pharmacogenomic testing has become a prime example of the utility of personalized molecular testing in the modern clinical laboratory. Warfarin is a commonly used drug for the prevention and treatment of thromboembolic complications in a variety of clinical situations. However, a number of factors lead to a high interindividual variability in dose requirements. Among the primary factors in this variability are genetic polymorphisms in general patient populations, which can account for 35-50% of varying dose requirements among patients. In this review, we discuss the implications of polymorphisms in the cytochrome P-450 enzyme 2C9 (CYP2C9) and Vitamin K Epoxide Reductase Enzyme Complex subunit 1 (VKORC1) as they relate to therapeutic warfarin dosing. We discuss the clinical utility of pharmacogenomics testing as related to warfarin dosing, and propose a clinical model for the implementation of the pharmacogenomic test results. Finally, we provide a brief overview of the currently available commercial testing platforms with discussion of the complexities of utilizing patented methodologies in bringing genetic testing such as this to the clinical laboratory.
Export Options
About this article
Cite this article as:
Borkowski A. Andrew, Kardani Avni, Mastorides M. Stephen and Thomas Brannon L., Warfarin Pharmacogenomics: Recommendations With Available Patented Clinical Technologies, Recent Patents on Biotechnology 2014; 8 (2) . https://dx.doi.org/10.2174/1872208309666140904112003
DOI https://dx.doi.org/10.2174/1872208309666140904112003 |
Print ISSN 1872-2083 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4012 |
Call for Papers in Thematic Issues
Advancements in Plant Genetics and Genomics
This thematic issue will highlight cutting-edge innovations and recent patents across the breadth of plant genetics and genomics. Key topics will include advanced breeding techniques, omics-based approaches, gene editing, trait discovery, and translational applications for crop improvement. Renowned researchers from leading institutions worldwide will provide state-of-the-art insights and future perspectives ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Crosstalk Between Insulin and Renin-Angiotensin-Aldosterone Signaling Systems and its Effect on Glucose Metabolism and Diabetes Prevention
Current Vascular Pharmacology Nutritional Support in Cancer
Current Nutrition & Food Science Preventing and Treating Anthracycline-Related Cardiotoxicity in Survivors of Childhood Cancer
Current Cancer Therapy Reviews SIRT1, a Calorie Restriction Mimetic, in a New Therapeutic Approach for Type 2 Diabetes Mellitus and Diabetic Vascular Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets Enediyne Anticancer Antibiotic Lidamycin: Chemistry, Biology and Pharmacology
Anti-Cancer Agents in Medicinal Chemistry Cardiac Output by Flotrac/VigileoTM Validation Trials: Are there Reliable Conclusions?
Reviews on Recent Clinical Trials Does Parkinson’s Disease and Type-2 Diabetes Mellitus Present Common Pathophysiological Mechanisms and Treatments?
CNS & Neurological Disorders - Drug Targets Lipoprotein Like Nanoparticles Used in Drug and Gene Delivery
Current Pharmaceutical Design PDE4D Gene in the STRK1 Region on 5q12: Susceptibility Gene for Ischemic Stroke
Current Medicinal Chemistry Neonatal Hypertension: An Underdiagnosed Condition, A Review Article
Current Hypertension Reviews Therapeutic Agents Based on DNA Sequence Specific Binding
Current Topics in Medicinal Chemistry The Role of Atypical Antipsychotic Agents in the Treatment of Schizophrenia and Schizoaffective Disorders in the Elderly
Current Drug Safety Sigma-1 Receptors: Potential Targets for the Treatment of Substance Abuse
Current Pharmaceutical Design The Pathogenesis of Susceptibility to Acute Kidney Injury in the Elderly
Current Aging Science Intracellular Fate of Peptide-Mediated Delivered Cargoes
Current Pharmaceutical Design Aetiology, Diagnosis and Treatment of Hydrops Foetalis
Current Pediatric Reviews Mitochondrial Mutations in Atherosclerosis: New Solutions in Research and Possible Clinical Applications
Current Pharmaceutical Design MicroRNAs in Peripheral Artery Disease
Current Topics in Medicinal Chemistry Angiotensin-(1-7), Angiotensin-Converting Enzyme 2 and Mas Receptor in Rat Polycystic Ovaries
Protein & Peptide Letters Pharmacotherapy in Type 2 Diabetes: A Functional Schema for Drug Classification
Current Diabetes Reviews